Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Market Yawns at BIIBs unimpressive 54 week ALZ drug results.
Biogen's 1st Poster from AAIC is up on website.
Go to Biogen website>Investor Relations>Presentations.
They have another one tomorrow regarding early detection of ALZ, understandable since the current study is Prodromal and Mild cases of ALZ.
See how the market reacts to both Biogen and Anavex on Monday.
If the market likes this presentation then Technically BIIB has mapped out an almost perfect cup and handle formation (late April to NOW) already and all would be sitting right at the break-out trigger point. This could be a HUGE gainer over the next few days IF the Market likes this Presentation at AAIC. However, just as likely to see a drop on the good ole Biotech "Sell the News' reaction.
I'm shocked about a non announcement for the buyout of anavex at this time
Biogen Appoints Catherine Steele Senior Vice President of Corporate Affairs
Source: Business Wire
Industry leader brings deep experience in communications, patient advocacy and government policy
Biogen (NASDAQ: BIIB) announced today the appointment of Catherine Steele as Senior Vice President of Corporate Affairs, effective July 17.
Ms. Steele, who brings more than 25 years of public affairs experience to Biogen, will lead the company’s corporate, product, and internal communications as well government affairs and patient advocacy efforts.
“Catherine is joining us at an exciting time in the evolution of Biogen,” said Chief Executive Officer Michel Vounatsos. “As we strengthen our pipeline, reaffirm our commitment to neuroscience and look to enter new therapeutic areas and markets globally, Catherine will play a crucial role in helping align our business with key public and patient audiences and establish Biogen with new stakeholders globally.”
Ms. Steele most recently served as Global Head, Communications and Patient Relations at Novartis Pharmaceuticals, where she was responsible for corporate reputation and helping drive external, internal and executive communication strategies. She also led the company’s social media and patient relations activities. Her career in the biopharma industry began at Roche, where she spent more than a decade in global communications and policy leadership roles.
"I am privileged to join Biogen, a respected and recognized pioneer in neuroscience," said Ms. Steele. "I look forward to building upon that legacy and being part of this company whose commitment to patients, families and society affected by neurological diseases is unwavering."
Ms. Steele holds dual undergraduate degrees in French and political science from the University of New Brunswick and a Master of Arts degree in political science from Carleton University.
About Biogen
Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology, and today the company has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics. For more information, please visit www.biogen.com. Follow us on social media – Twitter, LinkedIn, Facebook, YouTube.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170628005103/en/
Biogen
MEDIA CONTACT:
Matt Fearer, +1 781-464 3260
public.affairs@biogen.com
or
INVESTOR CONTACT:
Matt Calistri, +1-781-464-2442
IR@biogen.com
If they are buying anavex for 40 million
It's the best kept secret ever on Wall Street
It's nice to dream
Maybe waiting another few years is a better idea for a return on my money
I predict Anavex CEO Missling would tell them to go fly a kite if that was the offer. Maybe upfront payment and licensing for MS - nothing more.
I predict biogen announces that it is buying anavex life sciences for 40 billion dollars Tuesday
Biogen to Report Second Quarter 2017 Financial Results and Strategic Update on July 25, 2017
Source: Business Wire
Biogen Inc. (NASDAQ:BIIB) today announced it will report second quarter 2017 financial results and a strategic update on Tuesday, July 25, 2017, before the financial markets open.
Following the release of the financials, the Company will host a live webcast with Biogen management from 8:00-9:30 am ET. To access the live webcast, please go to the investor relations section of Biogen’s website at www.biogen.com/investors. Following the live webcast, an archived version of the call will be available at the same URL.
About Biogen
Through cutting-edge science and medicine, Biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics. For more information, please visit www.biogen.com. Follow us on social media – Twitter, LinkedIn, Facebook, YouTube.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170620005997/en/
Biogen
Karen Jewell, 781-464-2442
Investor Relations
Biogen Announces Management Change
Source: Business Wire
Biogen (NASDAQ: BIIB) announced today that Paul Clancy, Executive Vice President, Finance & Chief Financial Officer (CFO) will leave the organization to join another biopharmaceutical company. Mr. Clancy will remain at the Company through the second quarter and assist with the transition.
“I want to thank Paul for his more than sixteen years of distinguished service to Biogen, and especially for his last ten years as our CFO,” stated Michel Vounatsos, Biogen’s Chief Executive Officer. “Paul helped transform Biogen into the global biotechnology leader it is today and helped to prepare us for the bright future we believe lies ahead.”
Paul Clancy commented, “I am fortunate to have worked in such a remarkable organization and am pleased to have been a part of Biogen’s success. Biogen has a rich portfolio of products and pipeline and can look forward to even greater success under Michel’s leadership.”
The Company also announced that Greg Covino, Biogen’s Chief Accounting Officer, will serve as the Company’s interim Principal Financial Officer as the company conducts a search for a new CFO.
About Biogen
Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology, and today the company has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics. For more information, please visit www.biogen.com. Follow us on social media – Twitter, LinkedIn, Facebook, YouTube.
Biogen Safe Harbor
This press release contains forward-looking statements, made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements relating to Biogen’s business activities. These forward-looking statements may be accompanied by words such as “anticipate,” “believe,” “could,” “estimate,” “except,” “forecast,” “intend,” “may,” “plan,” “potential,” “possible,” “will” and other words and terms of similar meaning. You should not place undue reliance on these statements or the scientific data presented.
These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including, without limitation: risks relating to management and key personnel changes; failure to compete effectively; difficulties in obtaining and maintaining adequate coverage, pricing and reimbursement for our products; potential future healthcare reforms; the occurrence of adverse safety events; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; uncertainty of success in developing, licensing or acquiring other product candidates or additional indications for existing products; delay in approval of our drug candidates; product liability claims; and third party collaboration risks. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in Biogen’s most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securities and Exchange Commission. These statements are based on our current beliefs and expectations and speak only as of the date of this press release. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170613006328/en/
Biogen
MEDIA CONTACT:
Jason Glashow, +1 781-464-3260
public.affairs@biogen.com
or
INVESTOR CONTACT:
Matt Calistri, +1 617-679-3342
IR@biogen.com
An article on Biogen's failed MS drug.
Well, I made a few percent on this. And now I have sold. Beats money market!
I agree. Seems like a fairly high-probability scalp to buy in this range and ride it up to at least $290.
I have a feeling this is above 300 again by EOY
Jmho
Maybe I jumped back in too soon. Started buying at 252 and added more yesterday. I guess I would add even more if we see 230s.
Sure would be nice to see a 4M share day with a close up above 255...
I bet we see a nice buying opportunity here
Been waiting for this level
I'm likely adding soon
What's really funny is your lol
Post deleted
That's hysterical
Sorry
Albatross
Wow
Biogen loves the Tau technology
Read yesterday conference call transcript
Not enough information going forward
So far so good!
I wouldn't worry either way. The stock doesn't move due to Tom or Xena...unles the are representing institutions and buying/selling a ton.
No...what happened?
Did you happen to see the post about Tom P1
Yesterday
It came from Boston sports nut
Need to see this over 300 again
Patience $biib
Investors want Biogen to buy something to bolster revenues in the face of MS competition and patent challenges, as well as a lack of near-term catalysts. The company’s new chief executive officer, Michel Vounatsos, recently spoke at the Cowen & Company Annual Health Care Conference and suggested that, according to The Motley Fool, “more activity has gone on behind the scenes than meets the eye. He said that Biogen does want to bolster its pipeline with additional early-stage assets.”
OK I get it now as regards the Partnership,, Thanx!!
A good article on antisense which Biogen is partnering with Ionis for CNS.
http://www.alsa.org/news/vision-express/articles/april2016/the-neuro-collaborative.html?utm_source=natlnewsletter&utm_medium=email&utm_campaign=april2016
We will probably get approval for Alzheimer's in Australia first
I do not know how to answer that. If we have approval for alzheimers, then yes.
Do you think we will see 100 dollars per share in the next 18 months
Wondering if the Biogen spin off of Bioverativ is putting the announcement of Anavex partnership or possible buy out on hold.
If it's a buyout with an exchange of stock it would go over better with stockholders after rolling out Bioverativ as a shareholder dividend.
Also will Biogen be selling their share (did I read 25%?) for cash, and how much could it raise?
How might this affect an Anavex/Biogen transaction.
Helpful info on Bioverativ competition:
A little confusing here -
Is this just Biogen tying up loose ends for the Bioverativ launch?
Good summary of recent Biogen developments - but not advocating the site in general:
Looking good
$biib
Yep yep I know all about it
They just don't get it over there. The combo patent would extend the patent protection of the molecule used in the combo in the AD designation. Therefore you can sell the monotherapy knowing that the "unused" combo patent covers the molecule for AD sold by itself or not. Companies have many tricks to extend patents.
Have you read the Anavex initiated interview summary on the USPTO public PAIR database from 12-19 about the combo patent?
This is why I buy at multiple levels on the down tick ... Doesn't always go as far down as it "should"
Looking good now imo
Back up
Do I smell more news?
Ahhh...not sure why. Orvecko is the patent expert though. What people need to learn is how to use the public pair uspto database.
My reply to your private email suggested orveko name and background and comments
And very shortly after someone posted orveko name and patents
It threw me off a little
I'm pretty sure anavex will be a success
I just feel like it needs time
I am basing this on many positive developments
Including three new board members and their background and the comment missling made recently about looking forward to working with the MJFF
This doesn't prove the drug will work for Parkinson's but it's a start
I look forward to the next phase of testing in Australia
Time for a glass of wine
Happy holidays
Followers
|
43
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
627
|
Created
|
11/17/07
|
Type
|
Free
|
Moderators |
http://finance.yahoo.com/q/ks?s=BIIB
Biogen Idec Inc., a biotechnology company, develops, manufactures, and commercializes novel therapeutics in the areas of neurology, oncology, immunology, cardiopulmonary, and hemophilia in the United States and internationally. The company?s marketed products include AVONEX for the treatment of relapsing multiple sclerosis (MS); RITUXAN for treating relapsed or refractory, low-grade or follicular, CD20-positive, and B-cell Non-Hodgkin?s Lymphoma (NHL); TYSABRI to treat relapsing MS; and FUMADERM for the treatment of severe psoriasis. Its products under development consist of BG-12, a Phase III clinical trial product for the treatment of MS; Humanized Anti-CD20 MAb, a Phase III clinical trial product for the treatment of rheumatoid arthritis and lupus nephritis; Lixivaptan, a Phase III clinical drug for the treatment of Hyponatremia; Daclizumab, a Phase II monoclonal antibody that is being tested in relapsing MS; and Fampridine, an oral compound as a treatment to improve walking ability in people with MS. The company?s products under preclinical stage comprise BIIB014, Ocrelizumab, Neublastin, LINGO, and BART for neurology; Hsp90 Inhibitor, GA101, Anti-IGF-1R, Volociximab, Anti-CRIPTO, RAF Inhibitor, and Anti-Fn14 for oncology; Anti-TWEAK, Anti-CD40L Fab, and Anti-FcRn for immunology; and Long-acting rFactor VIII for hemophilia. It has collaboration agreements with Neurimmune SubOne AG; Cardiokine Biopharma LLC; UCB, S.A.; Swedish Orphan Biovitrum AB; Facet Biotech Corporation; Vernalis plc; and Schering AG. The company was founded in 1985 and is based in Cambridge, Massachusetts.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |